Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7609549 | 1.00 | DRD3 (0.32) | DRD3 | |
| Bromide SCHEMBL8331116 | 1.00 | DRD3 (0.32) | DRD3 | |
| SCHEMBL6777764 | 0.98 | — | — | |
| SCHEMBL476835 | 0.98 | — | — | |
| SCHEMBL9413931 | 0.98 | — | — | |
| SCHEMBL6213747 | 0.98 | — | — | |
| SCHEMBL7614249 | 0.98 | — | — | |
| SCHEMBL344353 | 0.98 | — | — | |
| SCHEMBL8360967 | 0.98 | — | — | |
| SCHEMBL4501561 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432948-B1 | ANTIULCER AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-0946176-B1 | THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES | BAYER AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |